Lois Borny works on the product review section of The Independent, IndyBest, where she helps readers to save money and shop savvy, scouting out the very best deals and sharing her tried and tested ...

Niktimvo’s launch, with newly approved vial sizes, complements this growth strategy, especially as it targets the underappreciated chronic indications such as cGvHD and IPF. The company’s ...

After hours: January 24 at 6:28:57 PM EST Loading Chart for SNDX ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00. The company’s shares closed yesterday at $72.41 ...

After hours: 7:40:05 p.m. EST ...